
|Articles|May 1, 2004
Medicare to cover PDT for select AMD patients
Washington, DC-The Centers for Medicare and Medicaid Services has begun to cover ocular photodynamic therapy (PDT) with verteporfin to treat select patients with subfoveal occult, but no classic choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) and subfoveal minimally classic CNV.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: The evolution of eye care on display at AAO 2025
2
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
3
Ocular pickleball injuries rise sharply with increasing game popularity
4
AAO 2025: Clinical outcomes of early vs delayed pegcetacoplan treatment in GA
5